180 related articles for article (PubMed ID: 34093791)
1. RECK expression is associated with angiogenesis and immunogenic Tumor Microenvironment in Hepatocellular Carcinoma, and is a prognostic factor for better survival.
Dong ZR; Chen ZQ; Yang XY; Ding ZN; Liu KX; Yan LJ; Meng GX; Yang YF; Yan YC; Yao SY; Yang CC; Zhi XT; Li T
J Cancer; 2021; 12(13):3827-3840. PubMed ID: 34093791
[TBL] [Abstract][Full Text] [Related]
2. RECK gene expression in hepatocellular carcinoma: correlation with invasion-related clinicopathological factors and its clinical significance. Reverse-inducing--cysteine-rich protein with Kazal motifs.
Furumoto K; Arii S; Mori A; Furuyama H; Gorrin Rivas MJ; Nakao T; Isobe N; Murata T; Takahashi C; Noda M; Imamura M
Hepatology; 2001 Jan; 33(1):189-95. PubMed ID: 11124835
[TBL] [Abstract][Full Text] [Related]
3. Somatic mutation and expression of BAP1 in hepatocellular carcinoma: an indicator for ferroptosis and immune checkpoint inhibitor therapies.
Yan YC; Meng GX; Ding ZN; Liu YF; Chen ZQ; Yan LJ; Yang YF; Liu H; Yang CC; Dong ZR; Hong JG; Li T
J Cancer; 2022; 13(1):88-101. PubMed ID: 34976173
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinoma.
Span PN; Sweep CG; Manders P; Beex LV; Leppert D; Lindberg RL
Cancer; 2003 Jun; 97(11):2710-5. PubMed ID: 12767082
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of reversion-inducing cysteine-rich protein with Kazal motifs expression in resected pathologic stage IIIA N2 non-small-cell lung cancer.
Takenaka K; Ishikawa S; Yanagihara K; Miyahara R; Hasegawa S; Otake Y; Morioka Y; Takahashi C; Noda M; Ito H; Wada H; Tanaka F
Ann Surg Oncol; 2005 Oct; 12(10):817-24. PubMed ID: 16132376
[TBL] [Abstract][Full Text] [Related]
6. Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer.
Takenaka K; Ishikawa S; Kawano Y; Yanagihara K; Miyahara R; Otake Y; Morioka Y; Takahashi C; Noda M; Wada H; Tanaka F
Eur J Cancer; 2004 Jul; 40(10):1617-23. PubMed ID: 15196549
[TBL] [Abstract][Full Text] [Related]
7. Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma.
Jia J; Ga L; Liu Y; Yang Z; Wang Y; Guo X; Ma R; Liu R; Li T; Tang Z; Wang J
Front Immunol; 2022; 13():923031. PubMed ID: 35924241
[TBL] [Abstract][Full Text] [Related]
8. Reversion-inducing cysteine-rich protein with Kazal motifs gene expression and its clinical significance in peripheral T-cell lymphoma.
Mao X; Liu L; Zhang B; Zhang D
Oncol Lett; 2013 Jun; 5(6):1867-1871. PubMed ID: 23833658
[TBL] [Abstract][Full Text] [Related]
9. Low expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung.
Takemoto N; Tada M; Hida Y; Asano T; Cheng S; Kuramae T; Hamada J; Miyamoto M; Kondo S; Moriuchi T
Lung Cancer; 2007 Dec; 58(3):376-83. PubMed ID: 17714826
[TBL] [Abstract][Full Text] [Related]
10. Reversion-inducing cysteine-rich protein with Kazal motif (RECK) expression: an independent prognostic marker of survival in colorectal cancer.
Stenzinger A; von Winterfeld M; Rabien A; Warth A; Kamphues C; Dietel M; Weichert W; Klauschen F; Wittschieber D
Hum Pathol; 2012 Aug; 43(8):1314-21. PubMed ID: 22397871
[TBL] [Abstract][Full Text] [Related]
11. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer.
Takeuchi T; Hisanaga M; Nagao M; Ikeda N; Fujii H; Koyama F; Mukogawa T; Matsumoto H; Kondo S; Takahashi C; Noda M; Nakajima Y
Clin Cancer Res; 2004 Aug; 10(16):5572-9. PubMed ID: 15328199
[TBL] [Abstract][Full Text] [Related]
12. Expression of matrix metalloproteinase regulator, RECK, and its clinical significance in osteosarcoma.
Xu J; Wu S; Shi X
J Orthop Res; 2010 Dec; 28(12):1621-5. PubMed ID: 20973064
[TBL] [Abstract][Full Text] [Related]
13. Reversion-Inducing-Cysteine-Rich Protein With Kazal Motifs (RECK) Gene Single Nucleotide Polymorphism With Hepatocellular Carcinoma: A Case-Control Study.
Bahgat DM; Shahin RM; Makar NN; Aziz AO; Hunter SS
J Clin Lab Anal; 2016 Jan; 30(1):36-40. PubMed ID: 25278269
[TBL] [Abstract][Full Text] [Related]
14. Prognostic role of RECK in pathological outcome-dependent buccal mucosa squamous cell carcinoma.
Chen HC; Tseng YK; Shu CW; Fu TY; Liou HH; Huang CH; Chen CC; Wang JS; Wu PC; Ger LP; Hung WC; Liu PF
Oral Dis; 2020 Jan; 26(1):62-71. PubMed ID: 31618798
[TBL] [Abstract][Full Text] [Related]
15. Recent Updates on the Therapeutic Prospects of Reversion-Inducing Cysteine-Rich Protein with Kazal Motifs (RECK) in Liver Injuries.
Palladini G; Di Pasqua LG; Croce AC; Ferrigno A; Vairetti M
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139236
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of reversion-inducing cysteine-rich protein with Kazal motifs in malignant melanoma: inverse correlation with membrane-type 1-matrix metalloproteinase and tissue inhibitor of metalloproteinase 2.
Jacomasso T; Trombetta-Lima M; Sogayar MC; Winnischofer SM
Melanoma Res; 2014 Feb; 24(1):32-9. PubMed ID: 24335752
[TBL] [Abstract][Full Text] [Related]
17. [miR-181c promotes the migration and angiogenesis of human A549 cells via targeting inhibition of reversion-inducing cysteine-rich protein with Kazal motifs (RECK)].
Liu C; Zhao F; Sun P; Han W; Hong M; Wu J; Zhang X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Dec; 38(12):1084-1090. PubMed ID: 36585230
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase-9 activity is associated with poor prognosis in T3-T4 node-negative colorectal cancer.
Cho YB; Lee WY; Song SY; Shin HJ; Yun SH; Chun HK
Hum Pathol; 2007 Nov; 38(11):1603-10. PubMed ID: 17669467
[TBL] [Abstract][Full Text] [Related]
19. Low expression of RECK indicates a shorter survival for patients with invasive breast cancer.
Zhang Y; Cheng S; Zhang G; Ma W; Liu Y; Zhao R; Zhang Q; Pang D
Cancer Sci; 2012 Jun; 103(6):1084-9. PubMed ID: 22404079
[TBL] [Abstract][Full Text] [Related]
20. RECK is not an independent prognostic marker for breast cancer.
Gomes LR; Fujita A; Mott JD; Soares FA; Labriola L; Sogayar MC
BMC Cancer; 2015 Oct; 15():660. PubMed ID: 26449734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
